HLA and cancer: Implications for cancer immunotherapy and vaccination

European Journal of Immunogenetics

Volumn 24, Issue 4, 1997, Pages 293-312

  Browning, M ^a   Dunnion, D ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 12; INTERLEUKIN 2; MELANOMA ANTIGEN; MELANOMA VACCINE; TUMOR ANTIGEN; HLA ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNOLOGY; IMMUNOLOGY; NEOPLASM; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; HLA ANTIGENS; HUMANS; NEOPLASMS; VACCINATION;

EID: 0031203892     PISSN: 09607420     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2370.1997.tb00025.x     Document Type: Review

References (108)

1. ANICHINI, A., FOSSATI, G. & PRMIANI, G. (1987) Clonal analysis of the cytolytic T cell response to human tumours. Immunology Today, 8, 385.
2. BARKER A., SCHREURS M., TAFAZZUL G., DE BOER A., KAWAKAMI Y., ADEMA G. & FIGDOR C. (1995) Identification of a novel peptide derived from the melanocyte-specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. International Journal of Cancer, 62, 97.
3. BARND D.L., LAN M.S., METZGAR R.S., & FINN O.J. (1989) Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proceedings of the National Academy of Sciences USA, 86, 7159.
4. EARTH A., HOON D.S.B., FOSHAG L.J., NIZZE J.A., FAMATIGA L., OKUN E. & MORTON D.L. (1994) Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Research, 54, 3342.
5. BERNHARD H., KARBACK J., WOLFEL T., BUSCH P., STORKEL S., STOCKLE M., WOLFEL T., SELIGER B., HUBER C., MEYER-ZUM-BUSCHENFELDE K.-H. & KNUTH A. (1994) Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. International Journal of Cancer, 59, 837.
6. BICKNELL, D.C., ROWAN, A. & BODMER, W.F. (1994) β2-microglobulin mutations: a study of established colorectal cell lines and fresh tumours. Proceedings of the National Academy of Sciences USA, 91, 4751.
7. BODMER, W.F., BROWNING, M.J., KRAUSA, P., ROWAN, A., BICKNELL, D.C. & BODMER, J.G. (1993) Tumour escape from immune response by variation in HLA expression and other mechanisms. Annals of the New York Academy of Science, 690, 42.
8. BOEL P., WILDMANN C., SENSI M.L., BRASSEUR R., RENAULD J.-C., COULIE P., BOON T. & VAN DER BRUGGEN P. (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2, 167.
9. BONAL F.J., PAREJA E., MARTIN J., ROMERO C. & GARRIDO F. (1986) Regression of Class I H-2K, H-2D antigens on GR9 methylcholanthrene induced tumour cell clones is related to the level of DNa methylation. Journal of Immunogenetics, 13, 179.
10. BOON T., VAN SNICK, J., VAN PEL, A., UYTENHO VE, C. & MARCHAND, M. (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte mediated cytolysis. Journal of Experimental Medicine, 152, 1184.
11. BORYSIEWICZ L.K., FLANDER A., NIMAKO M., MAN S., WILKINSON G.W., WESTMORELAND D., EVANS A., ADAMS M., STACEY S.N., BOURNSELL M.E.G., RUTHERFORD E., HICKLING J.K. & INGLIS S.C. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347, 1523.
12. BRICHARD V.G., HERMAN J., VAN PEL A., WILDMANN C., GAUGLER B., WOLFEL T., BOON T. & LETHE B. (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. European Journal of Immunology, 26, 224.
13. BROWNING, M.J., KRAUSA, P., ROWAN, A., BICKNELL, D.C., BODMER, J.G. & BODMER, W.F. (1993a) Tissue typing the HLA-A locus from genomic DNA by sequence specific PCR: comparison of HLA genotype and surface expression on colorectal tumour cell lines. Proceedings of the National Academy of Sciences USA, 90, 2842.
14. BROWNING, M.J., KRAUSA, P., ROWAN, A., HILL, A.B., BICKNELL, D.C., BODMER, J.G. & BODMER, W.F. (1993b) Loss of human leukocyte antigen expression on colorectal tumour cell lines: implications for anti-tumour immunity and immunotherapy. Journal of Immunotherapy, 14, 163.
15. BROWNING, M., PETRONZELLI, F., BICKNELL, D., KRAUSA, P., ROWAN, A., TONKS, S., MURRAY, N., BODMER, J. & BODMER, W.F. (1996) Mechanisms of loss of HLA class I expression on colorectal tumour cells. Tissue Antigens, 47, 364.
16. + cytotoxic T lymphocytes. Journal of Experimental Medicine, 181, 363.
17. CEREB N. & YANG S.Y. (1994) The regulatory complex of HLA Class I promoters exhibits locus specific conservation with limited allelic variation. Journal of Immunology, 152, 3873.
18. CERUNDOLO, V. & BRAUD, V. (1996) Cell biology of MHC class I molecules. In: HLA and MHC: Genes, Molecules and Function (ed. by M. Browning & A. McMichael), p. 193. BIOS Scientific Publishers, Oxford.
19. CHEN, L., LINSLEY, P.S. & HELLSTROM, K.E. (1993) Costimulation of T cells for tumour immunity. Immunology Today, 14, 483.
20. COLOMBO, M.P. & FORNI. G. (1994) Cytokine gene transfer in tumour inhibition and tentative tumour therapy: where are we now? Immunology Today, 15, 48.
21. COLONNA, M., BROOKS, E.G., FALCO, M., FERRARA, G.B. & STROMINGER, J.L. (1993) Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science, 260, 1121.
22. GORDON-CARDO C., FUKS Z., DROIBNJAK M., MORENO C., EISENBACH I & FELDMAN M. (1991) Expression of HLA-A,B,C antigens on primary and metastatic tumour cell populations of human carcinomas. Cancer Research, 51, 6372.,
23. COULIE, P.G. (1996) Human tumor antigens recognized by cytolytic T lymphocytes. In: Tumour Immunology: Immunotherapy and Cancer Vaccines (ed. by A.C. Dalgleish & M. Browning), p. 95. Cambridge, Cambridge University Press.
24. COULIE P.G., LEHMANN F., LETHE B., HERMAN J., LURQUIN C., ANDRAWISS M. & BOON T. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences, USA, 92, 7976.
25. COX A.L., SKIPPER J., CEHN Y., HENDERSON R.A., DARROW T.L., SHABANOWITZ J., ENGLEHARD V.H., HUNT D.F. & SLINGLUFF C.L. (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 264, 716.
26. CROMME, F.V., AIREY, J., HEEMALS. M.T., PLOUGH, H.L., KEATING, P.J., STERN, P.L., MEIJER C.J.L.M & WALBODMERS, J.M.M. (1994) Loss of transporter protein, encoded by the TAP-1 gene is highly correlated with loss of HLA expression in cervical carcinomas. Journal of Experimental Medicine, 179, 335.
27. D'URSO C.M., WANG Z., CAO Y., TATAKE R., ZEFF R.A. & FERRONE S. (1991) Lack of HLA Class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2m gene expression. Journal of Clinical Investigation, 87, 284.
28. DALGLEISH A.G. (1996) Co-stimulatory molecules and their role in tumor immunity. In: Tumour Immunology: immunotherapy and cancer vaccines. (Eds. Dalgleish A.G. and Browning M.) p. 185. Cambridge University Press, Cambridge.
29. DARROW, T.L., SLINGLUFF, C.L. & SEIGLER, H.F. (1989) The role of HLA class I antigens in recognition of melanoma cells by tumour specific cytotoxic T lymphocytes. Evidence for shared tumour antigens. Journal of Immunology, 142, 3329.
30. DOYLE, A., MARTIN, J., FUNA K., GAZDAR A., CARNEY D., MARTIN S.E., LINNOILA I., CUTTITTA F., MULSCHINE J., BUNN P. & MINNA J. (1985) Markedly decreased expression of class I histocompatibility antigens, protein and mRNA in human small cell lung cancer. Journal of Experimental Medicine, 161, 1135.
31. DUGGAN-KEEN M.F., KEATING P.J., STEVENS F.R.A., SINNOTT P., SNIJDERS P.J.F., WALBOOMERS J.M., DAVIDSEN S., HUNTER R.D., DYER P.A. & STERN P.L. (1996) Immunogenetic factors in HPV associated cervical cancer: influence on disease progression. European Journal of Immunogenetics, 23, 275.
32. ELLIS J.R.M., KEATING P.J., BAIRD J., HOUNSELL E.F., RENOUE D.V., ROWE, M., HOPKINS D., DUGGAN-KEEN M.F. BARTHOLOMEW J.S., YOUNG L.S. & STERN P.L. (1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine, 1, 464.
33. ESTEBAN F., CONCHA A., HUELIN C., PEREZ-AYALA M., PEDRINACI S., RUIZ-CABELLO F. & GARRIDO F. (1989) Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. International Journal of Cancer, 43, 436.
34. FEARON, E.R. & VOGELSTEIN, B. (1990) A genetic model for colorectal tumourigenesis. Cell, 61, 759.
35. FISK B., BLEVINS T.L., WHARTON J. & IOANNIDES C. (1995) Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cylotoxic T lymphocyte lines. Journal of Experimental Medicine, 181, 2109.
36. FLEMING, K., MCMICHAEL, A., MORTON, J., WOODS, J. & MCGEE, J. (1981) Distribution of HLA class I antigens in normal human tissue and in mammary cancer. Journal of Clinical Pathology, 34, 779.
37. FOLEY E.J. (1953) Antigenic properties of methylcholanthrene-induced tumours in mice of the strain of origin. Cancer Research, 13, 835.
38. GARRIDO, F., CABRERA, T., CONCHA, A., GLEW, S., RUIZ-CABELLO, F. & STERN, P. (1993) Natural history of HLA expression during tumour development. Immunology Today, 14, 491.
39. GAUGLER B., VAN DEN EYNDE B., VAN DER BRUGGEN P., ROMERO P., GAFORIO J.J., DE PLAEN E., LETHE B., BRASSEUR F. & BOON T. (1994) Human gene MAGE-3 coes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. Journal of Experiemental Medicine, 179, 921.
40. GENDLER S.J., TAYLOR-PAPADIMITRIOU J., DUHIG T., ROTHBARD J. & BURCHELL J. (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. Journal of Biological Chemistry, 263, 12820.
41. GIROLOMONI, G. & RICCIARDI-CASTAGNOLI, P. (1997) Dendritic cells hold promise for immunotherapy. Immunology Today, 18, 102.
42. GREENBERG, P.D. (1991) Adoptive T cell therapy of tumours: mechanisms operative in the recognition and elimination of tumour cells. Advances in Immunology, 49, 281.
43. GROSS L. (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Research, 3, 326.
44. HERIN, M., LEMOINE, C., WEYNANTS P., VESSIERE F., VAN PEL A., DEVOS R. & BOON T. (1987) Production of stable cytolytic T cell clones directed against autologous human melanoma. International Journal of Cancer, 39, 390.
45. IMREH M.P., ZHANG QJ., DE CAMPOS LIMA P.O., IMREH S., KRAUSA P., BROWNING M., KLEIN G. & MASUCCI M.G. (1995) Mechanisms of allele selective down-regulation of HLA class I in Burkitt's lymphoma. International Journal of Cancer, 62, 90.
46. IOANNIDES, C.G., FISK, B., FAN, BIDDISON, W.E., WHARTON, J.T. & O'BRIAN, C.A. (1993) Cytotoxic T cells isolated from ovarian malignant ascites recognise a peptide derived from the HER-2/neu proto-oncogene. Cellular Immunology, 151, 225.
47. IOANNIDES C.G., FEEDMAN R.S., PLATSOUCAS C.D., RASHED S. & KIM Y.-P. (1991) Cytotoxic T cell clones isolated from ovarian tumour infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumour cells. Journal of Immunology, 146, 1700.
48. ISRAEL, A. & KOURILSKY, P. (1996) Regulation of MHC class I gene expression. In: HLA and MHC: Genes, Molecules and Function (ed. by M. Browning & A. McMichael), p. 139. BIOS Scientific Publishers, Oxford.
49. KABAWAT, S., BAST, R.J., WELCH, W., KNAPP, R. & BHAN, A. (1983) Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. International Journal of Cancer, 32, 547.
50. KAGESHITA T., WANG Z., CALORINI L., YOSHI A., KIMURA T., ONO T., GATTONI-CELLI S. & FERRONE S. (1993) Selective loss of human leukocyte Class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of Class I human leukocyte antigens. Cancer Research, 53, 3349.
51. KAKLAMANIS, L., GATTER, K.C., HILL, A.B., MORTENSESN, N., HARRIS, A.L., KRAUSA, P., MCMICHAEL, A., BODMER, J.G. & BODMER, W.F. (1992) Loss of HLA class I alleles, heavy chains and β2-microglobulin in colorectal cancer. International Journal of Cancer, 51, 1.
52. KAKLAMANIS, L., TOWNSEND, A., DOUSSIS-ANAGNOSTOPOULOU, I.A., MORTENSEN, N., HARIS, A.L. & GATTER, K.C. (1994) Loss of major histocompatibility complex encoded transporter associated with antigen presentation (TAP) in colorectal cancer. American Journal of Pathology, 145, 505.
53. KANG, X.-Q., KAWAKAMI Y., SAKAGUCHI I.K., EL-GAMIL M., WANG R.-F., YANNELLI J.R., APPELLA E., ROSENBERG S.A. & ROBBINS P.F. (1995) Identification of a tyrosinase epitope recognized by HLA-A24 restricted tumour-infiltrating lymphocytes. Journal of Immunology, 155, 1343.
54. KARRE, K., LJUNGGREN, H.G., PIONTEK, G. & KIESSLING, R. (1986) Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature, 324, 575.
55. KAST, W.M., OFFRINGA, R., PETERS, P.J., VOORDOUW, A.C., MELDEN, R., VAN DER EB, A.J. & MELIEF, C.J.M. (1989) Eradication of adenovirus E1 -induced tumours by E1 A specific cytotoxic T lymphocytes. Cell, 59, 603.
56. KAWAKAMI Y., ELIYAHU S., SAKAGUCHI K., ROBBINS P.P., RIVOLTINI L., YANNELLI J.B., APPELLA E. & ROSENBERG S.A. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recog- nized by the majority of HLA-A2 restricted tumour infiltrating lymphocytes. Journal of Experimental Medicine, 180, 347.
57. KAWAKAMI Y., ELIYAHU S., JENNINGS C., SAKAGUCHI K., KANG, X.-Q., SOLITHWOOD S., ROBBINS P.F., SETTE A., APPELLA E. & ROSENBERG S.A. (1995) Recognition of multiple epitopes in the human melanoma antigen gp 100 associated with in vivo tumour regression. Journal of Immunology, 154, 3961.
58. KAWAKAMI, Y., ZAKUT, R., TOPALIAN. S.L., STOTTER, H. & ROSENBERG, S.A. (1992) Shared human melanoma antigens. Recognition by tumour infiltrating lymphocytes in HLA.1 transfected melanomas. Journal of Immunology, 148, 638.
59. KEATING P.J., CROMME F.V., DUGGAN-KEEN M., SNIJDERS P.J.F., WALBOOMERS J.M.M., HUNTER R.D., DYER P.A. & STERN P.L. (1995) Frequency of down regulation of individual HLA-A and B alleles in cervical carcinomas in relation to TAP-1 expression. British Journal of Cancer, 72, 405-411.
60. KLEIN, E., KLEIN, G., NADKARNI J.S. et al. (1967) Surface IgM specificity on cells derived from a Burkitt's lymphoma. Lancet ii, 1068.
61. KLEIN G., SJOGREN H.O., KELIN E. & HELLSTROM K.E. (1960) Demonstration of resistance against methylo- cholanthrene-induced sarcomas in the primary autochthonous host. Cancer Research. 20, 1561.
62. KLEIN, J. (1975) Biology of the Mouse Histocompatibility-2 Complex. Springer Verlag, Berlin.
63. LEHMANN, F., MARCHAND. M., HAINAUT, P., POUILLART, P., SASTRE, X., IKEDA, H., BOON, T. & COULIE. P.O. (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. European Journal of Immunology, 25, 340.
64. LJUNGGREN, H.G. & KARRE, K. (1990) In search of the 'missing self: MHC molecules and NK recognition. Immunology Today, 11, 237.
65. LYNCH, D.H. & MILLER, R.E. (1991) Immunotherapeutic elimination of syngeneic tumours in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumour-bearing mice. European Journal of Immunology, 21, 1403.
66. MARCHAND M., WEGMANTS P., RANKIN E., ARIENTI F., BELLI F., PARMIANI G., CASCINELLI N., BOURLOND A., VANWIJCK R., HUMBLET Y. et al. (1995) Tumour regression responses in melanoma patients treated with a peplide encoded by gene MAGE-3. International Journal of Cancer, 63, 883.
67. MARINCOLA, F.M., SHAMANIAN, P., ALEXANDER, R.B., GNARRA, J.R., TUTETSKAYA, R.L., NEDOSOPOV, S.A., SIMONIS, T.B., TAUBENBERGER, J.K., YANELLI, J., MIXON, A., RESTIFO, N.P., HERLYN, M. & ROSENBERG, S.A. (1994) Loss of HLA haplotype and B locus downregulation in melanoma cell lines. Journal of Immunology, 153, 1225.
68. MASCHEK U., PULM W. & HAMMERLING G.J. (1989) Altered regulation of MHC Class 1 gene in different tumour cell lines is reflected by distinct sets of DN'ase I hypersensitive sites. EMBO Journal, 8, 2297.
69. MELIEF, C.J.M., OFFRINGA, R., TOES. R.E.M. & KAST, W.M. (1996) Peptide based cancer vaccines. Current Opinion in Immunology, 8, 651.
70. MOLLER, P., HERRMANN, B., MOLDENHAUER, G. & MOMBURG, F. (1987) Defective expression of MHC class I antigens is frequent in B cell lymphomas of high grade malignancy. International Journal of Cancer, 40, 32.
71. MOMBURG, F., DEGENER, T., BACCHUS, L., MOLDENHAUER, G., HAMMERLING, G. & MOLLER, P. (1986) Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. International Journal of Cancer, 37, 179.
72. MORTON D.L., FOSHAG L.J., HOON D.S. NIZZE J.A., FAMATIGA F., WANEK L.A. CHANG C., DAVTYAN D.G., GUPTA R.K. & ELASHOFF R. (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals of Surgery, 216, 463.
73. MORTON D.L., HOON D.S. NIZZE J., FOSHAG L.J., FAMATIGA E., WANEK L.A., CHANG C., IRIE R.F., GUPTA R.K. & ELASHOFF R. (1993) Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Annals of the New York Academy of Sciences, 690, 120.
74. MORTON D.L. & RAVINDRANATH M.H. (1996) Current concepts concerning melanoma vaccines. In: Tumour Immunology: immunotherapy and cancer vaccines. (Eds. Dalgleish A.G. and Browning M.) p241. Cambridge University Press, Cambridge.
75. MUKHERJI B., CHAKRABORTY N.G., YAMASAKI S., OKINO T., YAMASE H., SPORN J.R., KURTZMAN S.K., ERGRIN M.T. OZOLS J., MEEHAN J. & MAURI F. (1995) Induction of antigen-specific cytolytic T cells in situ human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proceedings of the National Academy of Science USA. 92, 8078.
76. MUSIANI, P., MO DESTI, A., GIOVARELLI, M., CAVALLO, F., COLOMBO, M.P., LOLLINI, P.L. & FORNI, G. (1997) Cytokines. tumour cell death and immunogenicity : a question of choice. Immunology Today, 18, 32.
77. NATALI, P., NICOTRA, M., BIGOTTI A, VENTURO I., MARCENARO L., GIACOMINI P. & Russo C. (1989) Selective changes in expression of HLA class I polymorphic determinants in human solid tumours. Proceedings of the National Academy of Sciences USA, 86, 6719.
78. OLD L.J., BOYSE E. A. CLARK D. A. & CARSWELL E. A. (1962) Antigenic properties of chemically-induced tumours. Annals of the New York Academy of Science, 101, 80.
79. PATERSON Y. & IKONOMIDIS G. (1996) Recombinant Listeria monocytogenes cancer vaccines. Current Opinion in Immunology, 8, 664.
80. PEOPLES G.E., GOEDEGEBUURE P.S., SMITH R., LINEMAN D.C., YOSHINO I & EBERLEIN T.J. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proceedings of the National Academy of Sciences USA, 92, 432.
81. PREHN, R.T. & MAIN J.M. (1957) Immunity to methylcholanthrene-induced sarcomas. Journal of the National Cancer Institute, 18, 769.
82. REDONDO M., RUIZ-CABELLO F., CONCHA A., CABRERA T., PEREZ-AYALA M., OLIVA H.R. & GARRIDO F. (1991) Altered HLA Class I expression in non small cell lung cancer is independent of c-myc activation. Cancer Research, 51, 2463.
83. RESTIFO N. (1996) The new vaccines: building viruses that elicit antitumour immunity. Current Opinion in Immunology, 8, 658.
84. RESTIFO, N.P., ESQUIVEL, F., KAWAKAMI, Y., YEWDELL, J.W., MULE, J.J., ROSENBERG, S.A. & BENNINK, J.R. (1993) Identification of human cancers deficient in antigen processing. Journal of Experimental Medicine, 177, 265.
85. ROBBINS P.F., EL-GAMIL M., LI YF, KAWAKAMI Y., LOFTUS D., APPELLA E. & ROSENBERG S.A. (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumour infiltrating lymphocytes. Journal of Experimental Medicine, 183, 1185.
86. ROSA F., BERISSI H., WEISSENBACH J., MAROTEAUX L., FELLOUS M. & REVEL M. (1983) The β2 microglobulin in RNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO Journal, 2, 239.
87. ROSENBERG, S.A., PACKARD, B.S., AEBERSOLD, P.M., SOLOMON, D., TOPALIAN, S.L., TOY, ST., SIMON, P., LOTZE, M.T., YANG, J.C., SEIPP, C.A., SIMPSON, C., CARTER, C., BOCK, S., SCHWARTZENTRUBER, D., WEI, J.P. & WHITE, D.E. (1988) Use of tumour infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New England Journal of Medicine, 319, 1676.
88. SCHENDEL, D.J., GANSBACHER, B., OBERNADER, R., KRIEGMAIR M. HOTSTETTER, A., REITHMUELLER, G. & SEGURADO, O.G. (1993) Tumour specific lysis of human renal cell carcinomas by tumour infiltrating lymphocytes. I. HLA-A2 restricted recognition of autologous and allogeneic tumour cell lines. Journal of Immunology, 151, 4209.
89. SINGER, D.S. & MAGUIRE, J.E. (1990) Regulation of the expression of class I MHC genes. Critical Reviews in Immunology, 10, 235.
90. SLINGLUFF C.L., COX A.L., STOVER J.M., MOORE M.M., HUNT D.F. & ENGLEHARD V.H. (1994) Cytotoxic T lym-phocyte response to autologous squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Research, 54, 2731.
91. SMITH, M.E.F., MARSH, S.G.E., BODMER, J.G., GELSTHORPE, K. & BODMER, W.F. (1989) Loss of HLA-A, B, C allele products and lymphocyte function associated antigen 3 in colorectal neoplasia. Proceedings of the National Academy of Sciences USA, 86, 5557.
92. SOONG, T.W. & HUI, K.M. (1991) Identification of locus specific DNA binding factors for the regulation of HLA class I genes in human colorectal cancer. International Journal of Cancer 6 (supplement), 131.
93. TOMITA Y., MATSUMOTO Y., NISHIYAMA T. & FUJIWARA M. (1990) Reduction of major histocompatibility complex Class I antigens on invasive and high grade transitional cell carcinoma. Journal of Pathology, 162, 157.
94. TORRES, M.J., RUIZ-CABELLO, F., CABRERA, T., REAL, F.X. & GARRIDO, F. (1996) Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumour derived cell lines. Tissue Antigens, 47, 372.
95. TOSHITANI, K., BRAUD, V., BROWNING, M.J., MURRAY, N., MCMICHAEL, A.J. & BODMER, W.F. (1996) Expression of a single chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences USA, 93, 236.
96. TOWNSEND, A.R.M., GOTCH, F.M. & DAVEY, J. (1985) Cytotoxic T cells recognise fragments of influenza nucleo- protein. Cell, 42, 457.
97. TRAVERSARI C., VAN DER BRUGGEN P., LEUSCHER I.F., LURQUIN C., CHOMEZ P., VAN PEL A., DE PLAEN E., AMAR- COSTESEC A. & BOON T. (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A 1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. Journal of Experimental Medicine, 176, 1453.
98. UDONO, H., LEVEY, D.L. & SRIVASTAVAP. (1994) Cellular requirements for tumour specific immunity elicited by heat shock proteins: tumour rejection antigen gp96 primes CD8+ T cells in vivo. Proceedings of the National Academy of Sciences USA, 91, 3077.
99. VAN DEN EYNDE B., PEETERS O., DE BACKER O., GAUGHLER B., LUCAS S. & BOON T. (1995) A new family of genes coding for an antigen recognized by autologous cylolytic T lymphocytes on a human melanoma. Journal of Experimental Medicine. 182, 689.
100. VAN DER BRUGGEN P., BASTIN J., GAJEWSKI T., COULIE P.G., BOEL P., DE SMET C., TRAVKRSARI C., TOWNSEND A. & BOON T. (1994a) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recogniz.e tumour cells expressing MAGE-3. European Journal of Immunology, 24, 2038.
101. VAN DER BRUGGEN P., SZIKORA J.-P., BOEL P., WILDMANN C., SOMVILLE M., SENSI M. & BOON T. (1994b) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapcptide on melanomas expressing Cw 1601. European Journal of Immunology, 24, 2134.
102. VAN DER BRUGGEN, P., TRAVERSARI, C., CHOMEZ, P., LURQUIN, C., DE PLAEN, E., VAN DEN EYNDE, B., KNUTH, A. & BOON, T. (1991) A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643.
103. VEGH, Z., WANG, P., VANKY, F. & KEEIN, E. (1993) Selectively downregulated expression of MHC class I alleles in human solid tumours. Cancer Research, 53, 2416.
104. VERSTEEG. R., KRUSE-VOLTERS, K.M., PLOMP, A.C., VAN LEEUWEN, A., STAM, N.J., PLEOGH, H.L., RUITER, D.J. & SCHRIER, P.I. (1989) Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. Journal of Experimental Medicine, 170, 621.
105. WANG R.-F., PARKHURST M., KAWAKAMI Y., ROBBINS P.F. & ROSENBERG S.A. (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. Journal of Experimental Medicine, 183, 1131.
106. WÖEFEL T., HAUER M., SCHNEIDER J., SERRANO M., WOLFEI, C., KLEHMANN-HIEB E., DE PLAEN E., HANKEIN T. MEYER ZUM BUSCHENFELDE K.-H. & BEACH D. (1995) A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281.
107. WÖEFEL T., VAN PEL A., BRICHARD V., SCHNEIDER J., SELIGER B., MEYER ZUM BUSCHENFELDE K.-H. & BOON T. (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. European Journal of Immunology, 24, 759.
108. YASUMURA, S., HIRABAYASHI, H., SCHWARTZ, D.R., TOSO, J.F., JOHNSON, J.T., HERBERMAN, R.B. & WHITESIDE, T.L. (1993) Human cytotoxic T cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Research, 53, 1461.